Skip to content
Screener

Absci Corporation ABSI Deferred Revenue

Deferred Revenue at other companies

Schrodinger logo
SchrodingerSDGR
$63K-80.4%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$27.59M-30.5%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$20.71M+22.2%
Assembly Biosciences logo
Assembly BiosciencesASMB
$29.08M-28.8%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$1.09M+4.2%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$5.55M-62.2%

Other financials

Income statement

See full
Revenue$215.0K-81.8%
Operating income-$30.8M-11.2%
Net income-$29.6M-12.3%
EPS (diluted)-$0.19+9.5%

Balance sheet

See full
Cash & equivalents$9.7M-84.9%
Total debt$4.0M-37.2%
Total equity$172.0M-13.5%
Total assets$195.6M-15.9%

Cash flow

See full
Operating cash flow-$26.3M-20.5%
CapEx$30.0K+20.0%
Free cash flow-$26.3M-20.5%

Valuation

See full
Market cap$1.41B+235%
Enterprise value$1.4B+279%
P/S765.8×+664×

Profitability

See full
Operating margin-6,723%-14,525pp
Net margin-6,450.8%-13,699pp
FCF margin-5,365.2%-9,300pp

Returns & leverage

See full
Return on equity-63.9%+28.0pp
Debt / equity0.0×
Current ratio6.6×+0.9×

Where this comes from

Reported directly by Absci Corporation in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.

The source filing: Absci Corporation’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:24 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001672688-26-000088
(In thousands, except for share and per share data)March 31, 2026December 31, 2025
Accounts payable and accrued expenses$17,310$19,348
Long-term debt413873
Operating lease obligations1,8571,805
Deferred revenue450739
Total current liabilities20,03022,765
Operating lease obligations, net of current portion2,1452,624
Deferred revenue, long-term641436
Other long-term liabilities8061,023

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Absci Corporation's deferred revenue?
Absci Corporation (ABSI) reported deferred revenue of $450K in Q1 2026.
How has Absci Corporation's deferred revenue changed year-over-year?
Absci Corporation's deferred revenue decreased by 58.9% year-over-year, from $1.1M to $450K.
What is the long-term trend for Absci Corporation's deferred revenue?
Over 5 years (2020 to 2025), Absci Corporation's deferred revenue has grown at a -22.4% compound annual growth rate (CAGR), from $2.63M to $739K.
What does deferred revenue mean?
Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.

Ask your AI about Absci Corporation's deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude